0
0

Cart (0)

Home > Categories > Liraglutide

Liraglutide Impurities

Daicel offers a comprehensive range of impurities for Liraglutide, a peptide used in diabetes and obesity treatments. High-purity liraglutide impurity standards from Daicel enable precise impurity profiling, stability studies, and regulatory submissions for peptide-based metabolic therapies.

Sort by
Trp(5-OH)-Liraglutide

Trp(5-OH)-Liraglutide

  • CAT Number DCTI-D-000516
  • CAS NUMBER NA
  • MOLECULAR FORMULA C172H265N43O52
  • MOLECULAR WEIGHT 3767.26
Detailed View

Trp(Ac)-Liraglutide

  • CAT Number DCTI-D-000232
  • CAS NUMBER NA
  • MOLECULAR FORMULA C174H267N43O52
  • MOLECULAR WEIGHT 3793.3
Detailed View
Trp(O)-Liraglutide

Trp(O)-Liraglutide

  • CAT Number DCTI-D-000139
  • CAS NUMBER NA
  • MOLECULAR FORMULA C172H264N43O52
  • MOLECULAR WEIGHT 3766.25
Detailed View

Trp(O)25-Liraglutide Phosphate salt

  • CAT Number DCTI-D-000570
  • CAS Number NA
  • Molecular Formula C172H265N43O52
  • Molecular Weight 3767.26
Detailed View

α-Glu(side chain)-Liraglutide

  • CAT Number DCTI-D-000207
  • CAS NUMBER NA
  • MOLECULAR FORMULA C172H265N43O51
  • MOLECULAR WEIGHT 3751.56
Detailed View

β-Asp(9)-Liraglutide

  • CAT Number DCTI-D-000250
  • CAS NUMBER NA
  • MOLECULAR FORMULA C172H265N43O51
  • MOLECULAR WEIGHT 3751.26
Detailed View

β-Asp(9)-Liraglutide Phosphate Salt

  • CAT Number DCTI-D-000561
  • CAS NUMBER NA
  • MOLECULAR FORMULA C172H265N43O51
  • MOLECULAR WEIGHT 3751.26
Detailed View
LOAD MORE
You're viewed all 107 products
References
FAQ's

References

  1. Liselotte Bjerre Knudsen, Per Olaf Huusfeldt, Per Franklin Nielsen, Niels C. Kaarsholm, Helle Birk Olsen, S0ren Erik Bj0rn, Freddy Zimmerdahl Pedersen, Kjeld Madsen; Novo Nordisk A/S, “Derivatives of GLP-1 analogs”, Denmark, US patent, US 6,268,343 Bl, July 31, 2001
  2. Shah, Mubarak Hasan; Reddy, Padmanabha Reddy Yeragam; Bhawanishankar, Madhira; Raja, Mokkaisamy Jegadeesh; Pillai, Manoj,” UHPLC-MS/MS determination of GLP-1 analogue, liraglutide a bioactive peptide in human plasma”, European Journal of Biomedical and Pharmaceutical Sciences, Volume: 4, Issue: 3, Pages: 304-311, 2017

Frequently Asked Questions

Liraglutide impurities can be identified using analytical methods such as high-performance liquid chromatography (HPLC), liquid chromatography-mass spectrometry (LC-MS), etc.

Liraglutide impurities can be purified after synthesis using various techniques such as preparative HPLC, flash chromatography, or crystallization. These methods involve separating the impurities from the main product based on their chemical properties and physical characteristics.

Liraglutide impurities should be stored at recommended temperature conditions, typically 2-8°C or -20°C, depending on their stability. Improper storage can lead to degradation and loss of purity, so it's important to follow the manufacturer's instructions.

Liraglutide impurities can affect drug efficacy and safety. It is observed that impurities can cause adverse effects such as allergic reactions, injection site reactions, gastrointestinal disturbances, pancreatitis, or liver damage due to their toxicity or carcinogenic nature. Identifying and quantifying the impurities is essential during drug development.

Note: Products protected by valid patents by a manufacturer are not offered for sale in countries having patent protection. The sale of such products constitutes a patent infringement, and its liability is at the buyer's risk.

Back to Top
Product has been added to your cart